Form 4: BioMarin Executive Erin Burkhart Sells Shares Under 10b5-1 Plan

Erin Burkhart, GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 1,295 shares of common stock at $71.52 per share on March 19, 2025, under a pre-arranged 10b5-1 trading plan.

Summary

• On March 19, 2025, Erin Burkhart, the GVP and Chief Accounting Officer of BioMarin Pharmaceutical Inc., sold 1,295 shares of the company's common stock.
• The sale was executed at a price of $71.52 per share.
• This transaction was conducted under a pre-arranged 10b5-1 trading plan established on November 26, 2024.
• Following the transaction, Burkhart directly owns 16,955 shares of BioMarin common stock, adjusted to correct a previous clerical error of two shares.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing a stock sale by an executive. It doesn't inherently convey positive or negative sentiment.

Industry Context

Sales by company executives are a normal part of corporate governance. The use of a 10b5-1 plan indicates that the sales were pre-planned and not based on any inside information at the time of the transaction.

Comparison to Industry Standards

• Executive stock sales are common across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Vertex Pharmaceuticals also see regular Form 4 filings related to executive stock transactions.
• The use of 10b5-1 plans is a standard practice to avoid accusations of insider trading.

Stakeholder Impact

• The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the use of a 10b5-1 plan.

Key Dates

Keywords

BioMarin, BMRN, Form 4, Insider Trading, Erin Burkhart, 10b5-1 plan, Stock Sale, Chief Accounting Officer